Table 2.

Patient disposition based on cytogenetic risk* status.

	Standard risk		High risk†
Treatment discontinuation,‡ n (%)	D-Rd (n = 192)	Rd (n = 176)	D-Rd (n = 35)	Rd (n = 34)
Patients who discontinued treatment	105 (55)	148 (84)	26 (74)	31 (91)
Reason for discontinuation
Progressive disease	57 (30)	104 (59)	17 (49)	25 (74)
Adverse event	28 (15)	22 (13)	7 (20)	4 (12)
Noncompliance with study drug§	7 (4)	4 (2)	0	2 (6)
Withdrawal by patient	2 (1)	8 (5)	1 (3)	0
Physician decision	6 (3)	3 (2)	1 (3)	0
Death	3 (2)	5 (3)	0	0
Other	2 (1)	2 (1)	0	0

D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, FISH fluorescence in situ hybridization.

*Based on FISH/karyotyping.

^†Patients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality.

^‡Safety population.

^§Based on reason, “patient refused to further study treatment” at “end of treatment.”